Guidance to Market Authorization Holders on Issuing Health Product Risk Communications
Title | Guidance to Market Authorization Holders on Issuing Health Product Risk Communications PDF eBook |
Author | |
Publisher | |
Pages | 0 |
Release | 2022 |
Genre | Health products |
ISBN | 9780660431765 |
"The purpose of this document is to assist market authorization holders (MAHs) develop and disseminate health product risk communications (HPRCs). The guidance provided in this document is limited to HPRCs. An HPRC is a specific type of risk communication generated using the Health Canada-developed HPRC template and standardized process. HPRCs are designed to clearly and effectively communicate information to health care professionals about new health-related risks associated with marketed health products such as: drugs, medical devices, and natural health products. The guidelines and procedures described in this document assume that a decision to issue an HPRC has already been made. This document doesn't describe the criteria used to determine whether an HPRC is the ideal risk communication tool to address a particular risk"--Overview, page 1.
Guidance for Industry
Title | Guidance for Industry PDF eBook |
Author | |
Publisher | |
Pages | 32 |
Release | 2005 |
Genre | Consumer protection |
ISBN |
Draft Guidance Document - Triggers for Issuance of Risk Communication Documents for Marketed Health Products for Human Use
Title | Draft Guidance Document - Triggers for Issuance of Risk Communication Documents for Marketed Health Products for Human Use PDF eBook |
Author | |
Publisher | |
Pages | 51 |
Release | 2007 |
Genre | Consumer protection |
ISBN | 9780662463931 |
Health Product Risk Communication: Is the Message Getting Through?
Title | Health Product Risk Communication: Is the Message Getting Through? PDF eBook |
Author | The Expert Panel on Effectiveness of Health Product Risk Communication |
Publisher | Council of CanadianAcademies |
Pages | 212 |
Release | 2015-06-09 |
Genre | Health & Fitness |
ISBN | 1926522133 |
Communicating about risk cannot be reduced to a simple formula. There are a range of potential hazards that can pose risks to health, and these risks can vary in severity, certainty, probability, and complexity.
Reporting Adverse Reactions to Marketed Health Products
Title | Reporting Adverse Reactions to Marketed Health Products PDF eBook |
Author | |
Publisher | |
Pages | 43 |
Release | 2018 |
Genre | Electronic books |
ISBN | 9780660019628 |
'This guidance document provides market authorization holders (MAHs) with assistance on how to comply with the Food and Drugs Act, the Food and Drug Regulations, and the Natural Health Products Regulations with respect to reporting adverse reactions (ARs) to marketed health products'--Scope, p. 1.
Pain Management and the Opioid Epidemic
Title | Pain Management and the Opioid Epidemic PDF eBook |
Author | National Academies of Sciences, Engineering, and Medicine |
Publisher | National Academies Press |
Pages | 483 |
Release | 2017-09-28 |
Genre | Medical |
ISBN | 0309459575 |
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Sharing Clinical Trial Data
Title | Sharing Clinical Trial Data PDF eBook |
Author | Institute of Medicine |
Publisher | National Academies Press |
Pages | 236 |
Release | 2015-04-20 |
Genre | Medical |
ISBN | 0309316324 |
Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.